This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Adventrx Pharmaceuticals, Inc., (ANX) announced that the primary endpoint for response rate and the secondary endpoint for safety were met in the first stage of its Simon 2-stage design phase II trial using CoFactor to modulate the effect of 5- fluorouracil (5-FU) in patients with metastatic colorectal cancer.
We care about your feedback. Let us know how we can improve your CancerCompass experience.